Precision Microbiota Interventions for Senoreduction Trial

Starting soon · Phase 1/Phase 2

Conditions studied: HIV Infections, Alcohol Drinking, Aging, Immunosenescence

In brief

People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.

Key facts

Study ID

NCT07462767

Run by

Louisiana State University Health Sciences Center in New Orleans

People needed

160

Starts

2026-04-01

Expected to finish

2029-12-01

Last updated by the study team

2026-03-10

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥40 years
• People with HIV
• Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)

You may not qualify if…

• Probiotic use in past 3 months
• Recent antibiotics or immunosuppressives
• Allergy to study products
• Pregnancy or breastfeeding
• Inability to comply

Where it is running

• LSU Health — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.